PTGS2 and neoplasm: The interplay between COX-2 and IDO1 is further underpinned by studies in animal models of cancer, where pharmacological blockade of COX-2 translated into down-regulation of IDO1 expression at the tumour site, leading to decreased serum kynurenines [25,26].